Discontinued — last reported Q4 '25
Kinder Morgan Interest Paid increased by 128.2% to $623.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 5.2%, from $657.00M to $623.00M. Over 4 years (FY 2021 to FY 2025), Interest Paid shows an upward trend with a 4.3% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase in interest paid relative to debt levels may signal rising borrowing costs or higher leverage, while a decrease may indicate debt reduction or refinancing at lower rates.
The total cash outflow for interest payments on debt obligations, typically disclosed as a supplemental item in the cash...
Essential for comparing the cost of capital and debt burden across peers in the pharmaceutical industry.
cf_interest_paid| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $218.00M | $506.00M | $216.00M | $561.00M | $231.00M | $486.00M | $182.00M | $617.00M | $302.00M | $586.00M | $339.00M | $606.00M | $308.00M | $628.00M | $274.00M | $657.00M | $269.00M | $612.00M | $273.00M | $623.00M |
| QoQ Change | — | +132.1% | -57.3% | +159.7% | -58.8% | +110.4% | -62.6% | +239.0% | -51.1% | +94.0% | -42.2% | +78.8% | -49.2% | +103.9% | -56.4% | +139.8% | -59.1% | +127.5% | -55.4% | +128.2% |
| YoY Change | — | — | — | — | +6.0% | -4.0% | -15.7% | +10.0% | +30.7% | +20.6% | +86.3% | -1.8% | +2.0% | +7.2% | -19.2% | +8.4% | -12.7% | -2.5% | -0.4% | -5.2% |